Curanex Pharmaceuticals Inc
CURXHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeCuranex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. With a market capitalization of $7.3M, it sits in micro-cap territory. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Market Cap
$7.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-7.80
EPS (Fwd)
—
ROE
-411.1%
ROA
-225.1%
Cash
$2.9M
Total Debt
$276,359
Free CF
-$7.7M
52W Change
-64.9%
Annual Financials
Cash vs Debt
Where CURX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CURX finished 18.14% below its 150-day moving average ($6.01) and 21.66% below its 200-day moving average ($6.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CURX overbought or oversold?
At the October 20, 2026 close, CURX's RSI(14) was 49.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Curanex Pharmaceuticals Inc holds $2.9M in cash against $276K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$7.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -411.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $26K (2022) to $0 (2025), a 100% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Curanex Pharmaceuticals Inc's trajectory.